Zacks: Analysts Expect Alkermes Plc (ALKS) Will Announce Earnings of $0.17 Per Share
Equities research analysts forecast that Alkermes Plc (NASDAQ:ALKS) will report earnings of $0.17 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Alkermes’ earnings, with the highest EPS estimate coming in at $0.33 and the lowest estimate coming in at $0.08. Alkermes posted earnings of $0.15 per share during the same quarter last year, which suggests a positive year over year growth rate of 13.3%. The company is expected to report its next quarterly earnings results on Wednesday, February 21st.
According to Zacks, analysts expect that Alkermes will report full-year earnings of $0.01 per share for the current fiscal year, with EPS estimates ranging from ($0.12) to $0.18. For the next financial year, analysts expect that the business will report earnings of $0.24 per share, with EPS estimates ranging from ($0.24) to $0.63. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Alkermes.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. Alkermes had a negative return on equity of 12.18% and a negative net margin of 16.69%. The business had revenue of $217.40 million during the quarter, compared to analyst estimates of $231.29 million. During the same quarter in the prior year, the company posted ($0.09) EPS. Alkermes’s quarterly revenue was up 20.6% compared to the same quarter last year.
A number of research analysts have weighed in on ALKS shares. Jefferies Group set a $69.00 target price on Alkermes and gave the stock a “buy” rating in a report on Friday, August 25th. Credit Suisse Group set a $66.00 price target on Alkermes and gave the company a “buy” rating in a report on Tuesday, November 28th. J P Morgan Chase & Co set a $78.00 price target on Alkermes and gave the company a “buy” rating in a report on Friday, October 27th. Mizuho set a $81.00 price target on Alkermes and gave the company a “buy” rating in a report on Saturday, October 21st. Finally, Barclays cut Alkermes from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $66.00 to $50.00 in a report on Monday, October 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $63.55.
Alkermes (NASDAQ ALKS) traded up $1.06 during mid-day trading on Friday, hitting $52.62. The company’s stock had a trading volume of 2,574,029 shares, compared to its average volume of 981,681. Alkermes has a 1 year low of $46.42 and a 1 year high of $63.40. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23.
In other Alkermes news, SVP James M. Frates sold 20,932 shares of the stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $50.51, for a total value of $1,057,275.32. Following the completion of the sale, the senior vice president now owns 164,971 shares in the company, valued at approximately $8,332,685.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $51.98, for a total value of $51,980.00. Following the completion of the sale, the director now owns 9,000 shares of the company’s stock, valued at approximately $467,820. The disclosure for this sale can be found here. Insiders sold a total of 109,364 shares of company stock valued at $5,355,310 in the last quarter. 5.34% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of ALKS. Toronto Dominion Bank lifted its stake in Alkermes by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Alkermes in the third quarter worth about $126,000. Greenwood Capital Associates LLC raised its position in shares of Alkermes by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after acquiring an additional 41 shares during the period. Virtu Financial LLC acquired a new position in shares of Alkermes in the third quarter worth about $201,000. Finally, US Bancorp DE raised its position in shares of Alkermes by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after acquiring an additional 3,122 shares during the period. Hedge funds and other institutional investors own 99.69% of the company’s stock.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with Analyst Ratings Network's FREE daily email newsletter.